Chemotherapeutic inhibitors in the treatment of prostate cancer

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 1, 2014, Pages 11-22

  Deshmukh, Rahul R ^a   Schmitt, Sara M ^a   Hwang, Clara ^c   Dou, Qing Ping ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

Abiraterone; Androgen deprivation therapy; Androgen receptor signaling; Bicalutamide; Cabazitaxel; Castration resistant prostate cancer; Docetaxel; Enzalutamide; Estramustine; Flutamide; Ketoconazole; Megestrol; Mitoxantrone

Indexed keywords

ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; CABAZITAXEL; ENZALUTAMIDE;

ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCREENING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG INDUCED HEADACHE; FATIGUE; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERTENSION; MUSCULOSKELETAL PAIN; NONHUMAN; PROSTATE CANCER; REVIEW; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84890644843     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.852184     Document Type: Review

References (79)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29
2. George D, Moul JW. Emerging treatment options for patients with castration-resistant prostate cancer. Prostate 2012;72(3):338-49
3. Ohlmann CH, Merseburger AS, Suttmann H, et al. Novel options for the treatment of castration-resistant prostate cancer. World J Urol 2012;30(4):495-503
4. Saad F, Miller K. Treatment options in castration-resistant prostate cancer: Current therapies and emerging docetaxel-based regimens. Urol Oncol 2013; 5.
5. Arlen PM, Bianco F, Dahut WL, et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008;179(6):2181-5; discussion 85-6
6. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148-59
7. Linja MJ, Savinainen KJ, Saramaki OR, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61(9):3550-5
8. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164(1):217-27
9. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66(5):2815-25
10. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-9
11. Sridhar SS, Freedland SJ, Gleave ME, et al. Castration-resistant prostate cancer: From new pathophysiology to new treatment. Eur Urol 2013; doi: 10.1016/j.eururo.2013.08.008; Epub ahead of print
12. Connolly RM, Carducci MA, Antonarakis ES. Use of androgen deprivation therapy in prostate cancer: Indications and prevalence. Asian J Androl 2012;14(2):177-86
13. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168(1):9-12
14. Garnick MB, Fair WR. Combating prostate cancer. Sci Am 1998;279(6):74-83
15. Garnick MB, Gittelman M, Steidle C, et al. Abarelix (PPI-149), a novel and potent GnRH antagonist, induces a rapid and profound prostate gland volume reduction (PGVR) and androgen suppression before brachytherapy (BT) or radiation therapy (XRT). J Urol 1998;159:222a
16. Lepor H. The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Rev Urol 2006;8(4):183-9
17. Degarelix JA. A new GnRH antagonist, in prostate cancer. Comm Onocol 2009;6(5):197-9
18. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Ann Intern Med 2000;132(7):566-77
19. Labrie F, Dupont A, Belanger A, et al. New hormonal treatment in cancer of the prostate: Combined administration of an LHRH agonist and an antiandrogen. J Steroid Biochem 1983;19(1C):999-1007
20. Gao W, Bohl CE, Dalton JT. Chemistry and structural biology of androgen receptor. Chem Rev 2005;105(9):3352-70
21. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol 1993;149(3):607-9
22. Figg WD, Sartor O, Cooper MR, et al. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 1995;98(4):412-14
23. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;21(14):2673-8
24. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000;355(9214):1491-8
25. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969-74
26. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300(2):173-81
27. Schroder FH, Kurth KH, Fossa SD, et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: Results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study. J Urol 2004;172(3):923-7
28. Bogash M, Schneeberg JM, Perch GA, et al. Carcinoma of the Prostate: A Continuing Co-Operative Study. J Urol 1964;91:590-4
29. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet 1967;124(5):1011-17
30. Carcinoma of the prostate: Treatment comparisons. J Urol 1967;98(4):516-22
31. Bailar JC III, Byar DP. Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer 1970;26(2):257-61
32. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973;32(5):1126-30
33. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med 1984;311(20):1281-6
34. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist 2004;9(5):571-91
35. Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989;7(5):590-7
36. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005;353(16):1711-23
37. Beer TM, Pierce WC, Lowe BA, et al. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001;12(9):1273-9
38. Berry W, Dakhil S, Gregurich MA, et al. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001;28(4 Suppl 15):8-15
39. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT Investigators. J Clin Oncol 2007;25(6):669-74
40. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22(13):2532-9
41. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
42. Tucker WS Jr, Snell BB, Island DP, et al. Reversible adrenal insufficiency induced by ketoconazole. JAMA 1985;253(16):2413-14
43. Eichenberger T, Trachtenberg J, Toor P, et al. Ketoconazole: A possible direct cytotoxic effect on prostate carcinoma cells. J Urol 1989;141(1):190-1
44. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 2004;22(6):1025-33
45. BJ C, Pu YS H-J, HJ Y, et al. Ketoconazole in Taiwanese castration-resistant prostate cancer patients: Evaluation of response rates, durations, and predictors. Urol Sci 2012;23(2):48-51
46. Mazerski J, Martelli S, Borowski E. The geometry of intercalation complex of antitumor mitoxantrone and ametantrone with DNA: Molecular dynamics simulations. Acta Biochim Pol 1998;45(1):1-11
47. Perry CM, McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1995;7(1):49-74
48. Zhu ML, Horbinski CM, Garzotto M, et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010;70(20):7992-8002
49. Franke RM, Carducci MA, Rudek MA, et al. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 2010;28(30):4562-7
50. Naito S, Tsukamoto T, Koga H, et al. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: A multicenter Phase II trial in Japan. Jpn J Clin Oncol 2008;38(5):365-72
51. Joshua AM, Nordman I, Venkataswaran R, et al. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Intern Med J 2005;35(8):468-72
52. Saad DR, Ernst S, North E. Winquist Canadian Urologic Oncology Group (CUOG) phase II multi-center study using docetaxel/prednisone in the second line setting for metastatic hormone-refractory prostate cancer in patients progressing after first line mitoxantrone/prednisone. J Clin Oncol 2005;23(16S):4612
53. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756-64
54. Southwest Oncology G, Berry DL, Moinpour CM, et al. Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 2006;24(18):2828-35
55. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20
56. De Coster R, Wouters W, Bruynseels J. P450-dependent enzymes as targets for prostate cancer therapy. J Steroid Biochem Mol Biol 1996;56(1-6 Spec No):133-43
57. Potter GA, Barrie SE, Jarman M, et al. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alphahydroxylase- C17,20-lyase): Potential agents for the treatment of prostatic cancer. J Med Chem 1995;38(13):2463-71
58. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 2005;96(9):1241-6
59. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48
60. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005
61. Ezzell EE, Chang KS, George BJ. New agents in the arsenal to fight castrate-resistant prostate cancer. Curr Oncol Rep 2013;15(3):239-48
62. Simondsen K, Kolesar J. New treatment options for castration-resistant prostate cancer. Am J Health Syst Pharm 2013;70(10):856-65
63. Mukherji D, Pezaro CJ, Shamseddine A, et al. New treatment developments applied to elderly patients with advanced prostate cancer. Cancer Treat Rev 2013;39(6):578-83
64. Horwitz SB, Cohen D, Rao S, et al. Taxol: Mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993(15):55-61
65. Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2003;2(7):685-98
66. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15(2):723-30
67. Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008;19(9):1547-52
68. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;376(9747):1147-54
69. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-90
70. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010;375(9724):1437-46
71. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97
72. Golshayan AR, Antonarakis ES. Enzalutamide: An evidence-based review of its use in the treatment of prostate cancer. Core Evid 2013;8:27-35
73. El-Amm J, Freeman A, Patel N, et al. Bone-Targeted therapies in metastatic castration-resistant prostate cancer: Evolving paradigms. Prostate Cancer 2013;2013:210686
74. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31(4):412-19
75. Al-Asaaed S, Winquist E. Custirsen (OGX-011): Clusterin inhibitor in metastatic prostate cancer. Curr Oncol Rep 2013;15(2):113-18
76. McKeage K. Docetaxel: A review of its use for the first-line treatment of advanced castration-resistant prostate cancer. Drugs 2012;72(11):1559-77
77. Kucuk O, Fisher E, Moinpour CM, et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A Southwest Oncology Group study (SWOG 9235). Urology 2001;58(1):53-8
78. Lunglmayr G. Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group. Anticancer Drugs 1995;6(4):508-13
79. McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997;2(1):18-27